Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001048038 | SCV001212027 | pathogenic | not provided | 2024-10-08 | criteria provided, single submitter | clinical testing | This sequence change affects a donor splice site in intron 70 of the USH2A gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in USH2A are known to be pathogenic (PMID: 10729113, 10909849, 20507924, 25649381). This variant is present in population databases (rs767630412, gnomAD 0.007%). Disruption of this splice site has been observed in individual(s) with retinal dystrophy and/or USH2A-related conditions (internal data). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 845053). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. |
Blueprint Genetics | RCV001075770 | SCV001241402 | likely pathogenic | Retinal dystrophy | 2019-06-26 | criteria provided, single submitter | clinical testing | |
Gene |
RCV001048038 | SCV001823232 | likely pathogenic | not provided | 2020-09-16 | criteria provided, single submitter | clinical testing | Canonical splice site variant predicted to result in a null allele in a gene for which loss-of-function is a known mechanism of disease; Not observed at a significant frequency in large population cohorts (Lek et al., 2016); Has not been previously published as pathogenic or benign to our knowledge |
Genome- |
RCV003446597 | SCV004173893 | likely pathogenic | Retinitis pigmentosa 39 | 2023-04-11 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV003446597 | SCV004208210 | pathogenic | Retinitis pigmentosa 39 | 2024-03-23 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV001276140 | SCV001461992 | likely pathogenic | Usher syndrome type 2A | 2020-09-16 | no assertion criteria provided | clinical testing |